Endometrial adenocarcinoma is a heterogenous group of tumors with variable pathological, clinical, epidemiological, and genetic properties. Although, each of these perspectives contribute an aspect of understanding to the biology of this most common of all gynecological malignancies, they must be combined to achieve maximum benefit in patient care. This chapter is oriented along the simplified lines of a dichotomous model of sporadic disease in which the clinicopathological groups of endometrioid (type I) and nonendometrioid (type II) endometrial carcinomas are a launching point to consider their most commonly encountered characteristics. The former are subject to endocrine modulation and transit a PTEN tumor suppressor inactivated precursor stage of endometrial intraepithelial neoplasia (EIN), whereas the latter are characterized by p53 inactivation and a brief, if any, premalignant phase. A potential mechanism of unopposed estrogen promotion of endometrial carcinogenesis is its positive selection for PTEN-mutant epithelial cells, enabling clonal expansion and subsequent accumulation

From: Current Clinical Oncology: Molecular Pathology of Gynecologic Cancer Edited by: A. Giordano, A. Bovicelli, and R. Kurman © Humana Press Inc., Totowa, NJ

Norma glands

PTEN Mutation

Was this article helpful?

0 0
10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment